GSK to acquire RAPT Therapeutics for $2.2 billion, boosting immunology pipeline
GSK sits 48% above its 52-week low of $32.38.
Summary
GSK announced the acquisition of RAPT Therapeutics for an estimated $2.2 billion, gaining ozureprubart, a promising Phase IIb anti-IgE antibody for food allergies, to bolster its immunology pipeline.
Key Events · M&A and Partnerships · GSK
-
Acquisition Agreement
GSK has entered a definitive agreement to acquire RAPT Therapeutics.
-
Financial Terms
GSK will pay RAPT Therapeutics shareholders $58.00 per share, totaling an estimated aggregate equity value of $2.2 billion. The net upfront investment for GSK is $1.9 billion.
-
Key Asset Acquired
The acquisition includes ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody in Phase IIb clinical development for prophylactic protection against food allergens.
-
Strategic Rationale
This acquisition adds a potentially best-in-class treatment to GSK's Respiratory, Immunology & Inflammation pipeline, addressing a significant unmet medical need in food allergies with a therapy offering less frequent dosing.
Analysis · GSK · Life Sciences
The acquisition of RAPT Therapeutics for an estimated $2.2 billion significantly enhances GSK's immunology pipeline. The primary asset, ozureprubart, is a long-acting anti-IgE antibody in Phase IIb development for food allergies, a condition with substantial unmet medical need. This strategic move aligns with GSK's focus on acquiring assets that address validated targets and offer improved patient outcomes, such as less frequent dosing compared to current therapies. The transaction is expected to close in Q1 2026, positioning GSK to further expand its presence in the allergy treatment market.
At the time of this filing, GSK was trading at $48.01 on NYSE in the Life Sciences sector, with a market capitalization of approximately $98.3B. The 52-week trading range was $32.38 to $51.46. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.